

FOI 2895

12th March 2025

Dear Sir/Madam

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1: How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in Q4'24 (October, November, December 2024)?

a. With BPA/Hemlibra Inhibitor?

Response: The Southern Trust does not look after congenital or acquired haemophilia patients in the Southern Trust unless as an emergency if they present to CAH ED bleeding.

The care of patients with the diagnoses listed above is directed by Haematology clinical staff in the Belfast Trust for all of Northern Ireland. This would include care for any surgical procedures, which would also typically be undertaken at a Belfast trust hospital site.

You may wish to direct your question to the Belfast Health & Social Care Trust. Their email address is as follows: publicliaison@belfasttrust.hscni.net

Question 2: Please fill in the BPA/Hemlibra products *utilized* in October, November, December 2024

October through December 2024		Q4'24 Volume (IU)/mg		Total Patients	Patients	
					Prophylaxis	On demand
	<i>Example: FEIBA</i>	<i>50,000 IU</i>		<i>1</i>	<i>0</i>	<i>0</i>
Hem A Inhibitor Patients						
Haem A Inhibitor Patients	FEIBA					
	Cevenfacta					
	NovoSeven					
	Hemlibra					
	FEIBA					
	Cevenfacta					

Haem B Inhibitor Patients	NovoSeven				
	Obizur				
AHA Patients					
AHA Patients	FEIBA				
	NovoSeven				
	Obizur				
	Cevenfacta				
	Hemlibra				
Other Use					
FVII deficient	NovoSeven				
Glanzmann's	NovoSeven				
Other	NovoSeven				
Other	Cevenfacta				

Response: <5.

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

The Southern Trust does not look after congenital or acquired haemophilia patients in the Southern Trust unless as an emergency if they present to CAH ED bleeding.

Question 3: How many minor and major surgeries did your BPA patients have in October, November, December 2024?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

Response: See response to Question 1

Question 4: How many minor and major surgeries did your BPA/Hemlibra inhibitor patients have in October, November, December 2024

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

Response: See response to Question 1

Question 5: How many breakthrough bleeds did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	Inhibitor patients	Q4'24 volume (IU/mg)
Hemlibra		
NovoSeven		
FEIBA		

Response: See response to Question 1

Question 6: Were there any changes in the total number of acute bleeds treated with factor in Q4'24 as compared to Q3'24?

Response: See response to Question 1

Question 7: Was there any change in the number of elective surgeries using factor in Q4'24 as compared to Q3'24?

<i>Number of Surgeries</i>	<i>BPA</i>
Increase / Decrease / Stable compared to Q3'24?	
How many surgeries occurred in Q4'24?	

Response: See response to Question 1

Question 8: Have any BPA patients switched products between October 1st through December 31st 2024? What were the reasons for the switches?

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
<i>Example: Haem B Inh.</i>	<i>1 NovoSeven</i>	<i>On-demand</i>	<i>Cevenfacta</i>	<i>Prophy 1x/week</i>	<i>Severe</i>	<i>Patient requested to try out a new product to improve treatment</i>

Response: See response to Question 1

Question 9: What is the total number of patients treated with NovoSeven at your Trust?

Response: See response to Question 1

Email: Foi.Team@Southerntrust.hscni.net